Navigation Links
Cepheid to Webcast Analyst Event
Date:7/21/2008

Management presentations to be hosted at 2008 American Association for

Clinical Chemistry Annual Meeting

SUNNYVALE, Calif., July 21 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today invited investors to participate in the Company's Analyst Reception which is being hosted in Washington, D.C. ahead of the 2008 American Association for Clinical Chemistry (AACC) Annual Meeting.

Cepheid speakers will include Chief Executive Officer John Bishop, Chief Medical and Technology Officer David Persing, Chief Operations Officer Humberto Reyes, Senior Vice President of Worldwide Commercial Operations, Rob Koska, and Chief Financial Officer Andrew Miller.

Investors and interested parties are welcome to access the live webcast that will be available starting at 5:30 p.m. Eastern Time on Monday, July 28, 2008. The program is expected to last up to three hours. To access the live webcast, please visit Cepheid's website at http://www.cepheid.com/investors at least 15 minutes before the scheduled start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the call and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

For Media Inquiries:

Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400 8377

jared.tipton@cepheid.com

For Investor Inquiries:

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400 8329

jacquie.ross@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Schedules Fiscal 2008 Second Quarter Financial Results Announcement and Webcast
2. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
3. Cepheid Market Reach Extended with Licenses in Canada and Registrations in Mexico
4. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
5. Cepheid to Present at the Robert W. Baird Growth Stock Conference and the Bank of America Healthcare Conference
6. Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results
7. Cepheid to Present at Cowen and Companys 28th Annual Healthcare Conference
8. Cepheid Reports Fourth Quarter and Full Year 2007 Results
9. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
10. Cepheid Appoints Senior VP, Chief Financial Officer to Management Team
11. Cepheid Schedules Teleconference and Webcast for 2007 Fourth Quarter and Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):